Equities

Rion Co Ltd

Rion Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)2,417.00
  • Today's Change11.00 / 0.46%
  • Shares traded11.90k
  • 1 Year change+10.62%
  • Beta1.7239
Data delayed at least 15 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RION CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and environmental equipment. The Company operates in two business segments. The Medical Equipment manufactures and sells hearing aids and training equipment for hearing impaired people, as well as audiometers and hearing testing equipment. The Environmental Equipment segment provides sound level meters, vibration meters, seismometers and frequency analyzers, as well as air particle counters and liquid particle counters.

  • Revenue in JPY (TTM)26.67bn
  • Net income in JPY2.59bn
  • Incorporated1944
  • Employees1.03k
  • Location
    Rion Co Ltd3-20-41, Higashimoto-machiKOKUBUNJI-SHI 185-8533JapanJPN
  • Phone+81 423597830
  • Fax+81 423597447
  • Websitehttps://www.rion.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kusurinomadoguchi Inc9.91bn897.35m15.11bn505.0016.302.187.281.5284.4384.43943.55630.970.5277--3.0319,623,970.004.71--15.84--57.76--8.92----31.520.034--17.53--122.49------
Techno Medica Co Ltd10.34bn1.19bn15.91bn237.0010.860.925212.221.54167.16167.161,442.431,962.830.60312.254.4543,647,340.006.966.688.047.8049.9848.8611.5312.314.51138.020.0039.339.781.9617.154.190.71687.67
Daiken Medical Co Ltd9.84bn1.06bn16.05bn175.0013.661.9912.501.6336.8936.89342.51253.630.86933.903.8756,226,790.009.367.4413.2510.8441.3341.7410.779.281.90301.850.252771.356.713.0138.843.03-4.010.9806
Japan Medical Dynamic Marketing, INC.24.04bn1.41bn16.42bn511.0011.590.65785.300.682753.4953.49913.02942.480.78060.67184.5347,051,430.004.716.515.447.5363.4166.976.048.881.82--0.089518.338.786.74-10.68-8.52-2.959.24
Medical Data Vision Co Ltd6.06bn4.79m17.33bn262.003,452.404.44242.452.860.12540.1254158.5997.571.12252.238.5323,120,150.00-0.465216.16-0.636720.8875.6881.90-0.414715.522.594.570.0019.985.1512.4012.4869.75-23.95--
Medius Holdings Co Ltd268.79bn1.11bn17.43bn2.52k15.610.89715.830.064950.2450.2412,186.68873.942.4918.804.97106,790,700.001.031.733.986.3411.9111.830.41120.65650.9191--0.563728.328.675.62-24.92--16.488.45
Japan Tissue Engineering Co., Ltd.2.43bn-70.51m20.06bn211.00--3.43266.848.26-1.74-1.7459.82144.180.36634.635.3811,513,990.00-1.06-4.72-1.19-5.3163.2957.30-2.90-16.387.97-295.270.00--23.701.29119.63--30.22--
Findex Inc6.03bn1.32bn21.61bn290.0015.743.9515.403.5851.6051.60234.94205.651.076.885.6720,784,770.0023.5715.7225.9818.4163.0256.8121.9314.588.30----36.2014.327.5846.5421.62-3.3411.63
Rion Co Ltd26.67bn2.59bn29.68bn1.03k11.430.98488.091.11210.52210.522,165.882,443.260.72271.734.1225,990,020.007.036.278.177.2550.4050.299.728.852.41--0.0028.117.793.8647.395.7825.244.56
Mizuho Medy Co Ltd10.99bn3.50bn30.86bn180.008.831.918.302.81183.56183.56576.85846.830.59721.692.6061,046,260.0019.0131.4621.2539.7871.8874.8531.8333.647.62--0.0034.83-37.4911.34-51.8532.64-17.7432.85
Nippon Care Supply Co., Ltd.30.49bn1.67bn31.05bn1.33k17.751.833.731.02107.69107.691,962.131,045.341.21119.7527.3122,853,900.006.657.619.629.9435.2037.585.496.780.6264--0.160556.7510.4310.474.212.0724.048.76
Win-Partners Co Ltd80.84bn1.98bn37.34bn629.0017.661.5317.090.461969.2969.292,830.28798.131.8824.194.87128,518,700.004.604.398.318.0612.2812.502.452.681.68--0.0063.188.762.01-10.33-7.0140.619.34
Data as of Nov 22 2024. Currency figures normalised to Rion Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

18.05%Per cent of shares held by top holders
HolderShares% Held
Asset Management One Co., Ltd.as of 14 Jun 2024745.40k6.04%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 31 Oct 2024408.30k3.31%
Nomura Asset Management Co., Ltd.as of 07 Nov 2024300.60k2.44%
Kamakura Investment Management Co., Ltd.as of 19 Jul 2023244.90k1.99%
Dimensional Fund Advisors LPas of 07 Nov 2024138.63k1.12%
Nikko Asset Management Co., Ltd.as of 08 Nov 2024121.40k0.98%
Daiwa Asset Management Co. Ltd.as of 31 Oct 2024114.80k0.93%
Sawakami Asset Management, Inc.as of 30 Aug 202460.20k0.49%
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 202452.20k0.42%
SBI Asset Management Co., Ltd.as of 22 Jan 202440.00k0.32%
More ▼
Data from 19 Jul 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.